Waverly Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Waverly Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$279K	Sell	4,877 -1,799	-27%	-$98.5K	﹤0.01%	1450
2026 Q1	$377K	Buy	6,676 +1,617	+32%	+$94.3K	﹤0.01%	1212
2025 Q4	$301K	Sell	5,059 -126	-2%	-$6.86K	﹤0.01%	1202
2025 Q3	$281K	Buy	+5,185	New	+$297K	﹤0.01%	1067
2014 Q1	–	Sell	-46	Closed	-$3K	–	700
2013 Q4	$3K	Buy	+46	New	+$3.12K	﹤0.01%	735

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Waverly Advisors's BMRN Position: Q2 2026 in Review

Waverly Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 27% in Q2 2026, selling an estimated $98.5K and leaving 4,877 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #1450.

Waverly Advisors first reported a position in BMRN in Q4 2013 and has held it in 5 quarters since. The position peaked at $377K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Waverly Advisors held 4,877 shares of BioMarin Pharmaceuticals worth $279K as of Q2 2026.
Waverly Advisors sold 1,799 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $98.5K.
BioMarin Pharmaceuticals made up ﹤0.01% of Waverly Advisors's portfolio in Q2 2026, its #1450 holding.
Waverly Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 5 quarters since.
Waverly Advisors's BioMarin Pharmaceuticals position peaked at $377K in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Waverly Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.